» Articles » PMID: 8970871

Noninvasive Monitoring of Intraocular Pharmacokinetics of Daunorubicin Using Fluorophotometry

Overview
Journal Int Ophthalmol
Specialty Ophthalmology
Date 1995 Jan 1
PMID 8970871
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Daunorubicin is a cytotoxic drug, which, in nontoxic doses, is effective in preventing cellular proliferation in experimental vitreoretinopathy. We studied dose and clearance of daunorubicin in various ocular tissues using fluorophotometry techniques.

Methods: In vitro tests: The emission of fluorescence from the daunorubicin solution having a concentration range of 0.1 to 10 micrograms/mL in phosphate buffer was measured using an excitation wavelength range of 489 +/- 10 nm. The emission of fluorescence was measured at 514 nm; the linearity of the response was determined using linear regression analysis. There is a fluorescence peak of daunorubicin at 485 nm. The validity and reproducibility of the method were examined. In vivo tests: The rabbits were randomized into three groups and daunorubicin concentrations of 4, 6, or 8 micrograms/mL were injected into the vitreous. Fluorophotometry scanning from the retina to the anterior chamber was performed with a commercially available fluorophotometer at various times up to 48 hours after injection to quantify fluorescence emission of daunorubicin.

Results: The standard curve of fluorescence versus concentration of daunorubicin was linear in the range of 0.1 to 8 micrograms/mL. It was sensitive up to 0.1 microgram. The daunorubicin time concentration profile showed a dose response relationship over the 48-hour period studied. The half-life of daunorubicin in the vitreous was about 5 hours.

Conclusion: We performed fluorophotometry using a fluorophotometer whose exciter emits light at 489 nm, which is very close to an absorption peak of daunorubicin. These two values are close enough to obviate the need for modifying the commercial fluorophotometer. Therefore the concentration of daunorubicin in the vitreous cavity can be measured noninvasively.

Citing Articles

A sustained dual drug delivery system for proliferative vitreoretinopathy.

Xiao Y, Choi K, Warther D, Huffman K, Landeros S, Freeman W Drug Deliv. 2020; 27(1):1461-1473.

PMID: 33100053 PMC: 7594716. DOI: 10.1080/10717544.2020.1833382.


A novel lipid prodrug strategy for sustained delivery of hexadecyloxypropyl 9-[2-(phosphonomethoxy)ethyl]guanine (HDP-PMEG) on unwanted ocular proliferation.

Chen M, Hou J, Tan G, Xie P, Freeman W, Beadle J Drug Deliv. 2017; 24(1):1703-1712.

PMID: 29115885 PMC: 8241053. DOI: 10.1080/10717544.2017.1399303.


Real-time monitoring of sustained drug release using the optical properties of porous silicon photonic crystal particles.

Wu E, Andrew J, Cheng L, Freeman W, Pearson L, Sailor M Biomaterials. 2010; 32(7):1957-66.

PMID: 21122914 PMC: 3025697. DOI: 10.1016/j.biomaterials.2010.11.013.

References
1.
Handa K, Sato S . Generation of free radicals of quinone group-containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation. Gan. 1975; 66(1):43-7. View

2.
Patel D, Canuel L . Anthracycline antitumor antibiotic nucleic-acid interactions. Structural aspects of the daunomycin poly(dA-dT) complex in solution. Eur J Biochem. 1978; 90(2):247-54. DOI: 10.1111/j.1432-1033.1978.tb12597.x. View

3.
Khawly J, Saloupis P, Hatchell D, MACHEMER R . Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1991; 229(5):464-7. DOI: 10.1007/BF00166311. View

4.
Steinhorst U, Hatchell D, Chen E, MACHEMER R . Ocular toxicity of daunomycin: effects of subdivided doses on the rabbit retina after vitreous gas compression. Graefes Arch Clin Exp Ophthalmol. 1993; 231(10):591-4. DOI: 10.1007/BF00936524. View

5.
Handa K, Sato S . Stimulation of microsomal NADPH oxidation by quinone group-containing anticancer chemicals. Gan. 1976; 67(4):523-8. View